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Abstract The aim of the study was to determine an
association of TP53 codon 72 (Arg72Pro, G[C transver-
sion, rs1042522) and MDM2 SNP309 (T[G change,
rs2279744) polymorphisms in endometrial cancer (EC) of
postmenopausal women, regarding grading and staging of
EC. In the study, endometrial samples from 202 post-
menopausal female patients (the study group, n = 152, was
women with EC; the control group, n = 50, cancer-free
patients) were taken for the evaluation of two gene poly-
morphisms: TP53 codon 72 and MDM2 SNP309, respec-
tively. Genotypic analyses were performed using the PCR–
RFLP technique. There were significant differences in the
frequency of TP53 and MDM2 genotypes in EC patients—
increased EC occurrence was observed with the presence
of MDM2 G/G and TP53 Arg/Arg genotypes, while allele
Pro of TP53 decreased cancer risk. Analysis of combined
MDM2/TP53 polymorphisms revealed that T/T-Pro/Arg
genotype decreased EC risk, whereas G/G-Arg/Arg geno-
type increased it. Association of these genetic polymor-
phisms with histological grading showed increased MDM2
G/G homozygote and TP53 Arg/Arg homozygote fre-
quencies in grading 2 as well as allele G overrepresentation
in G1 and G3 EC patients. Finally, with clinical FIGO
staging under evaluation, an increase in MDM2 G/G and
TP53 Arg/Arg homozygote frequencies in staging I and
TP53 Arg/Arg homozygote frequencies in staging II were
observed. Co-occurrence of some MDM2 SNP309 and
TP53 codon 72 polymorphisms seems to influence EC risk,
involving grading and staging of this neoplasm at the same
time.
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Introduction
Genetic base of endometrial cancer (EC), the most frequent
neoplasm of sex organs in postmenopausal women, is not
fully understood. Among numerous genes postulated to be
involved in EC oncogenesis, at least two seem to play here
an important role. These genes—MDM2 and TP53—are
taking part in cell-cycle regulation. The first one—
MDM2—belongs to proto-oncogenes, or proliferation
genes responsible for cell growth and differentiation. The
second one—TP53—is a suppressor gene preventing
genetic anomalies transmission to daughter cells. TP53 in
the moment of DNA strand damage inhibits cells in G1
phase and runs repair mechanisms or apoptosis when
damage is too much [1, 2].
From oncogenic point of view extremely important
appears to be that action of these two genes is interrelated:
Protein product of TP53 gene—p53 protein—has the
ability to activate (a number of genes including) MDM2
gene, resulting in an increased production of mdm2 pro-
tein, which in turn inhibits p53 protein activity and by
reducing its suppressor properties may initiate the process
of carcinogenesis, including EC as well [3]. Any disruption
in MDM2/TP53 genes may underlie EC development.
Unfortunately, data on the occurrence of specific MDM2/
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TP53 mutations or polymorphisms in EC are scant, mostly
analyzing each gene separately, not together [4, 5].
The aim of this present work was to change the existing
situation and to determine the potential relationship
between TP53 codon 72 and MDM2 SNP309 polymor-
phisms in EC of postmenopausal women, regarding histo-




A total of 152 patients with histologically proven diagnosis of
endometrial cancer were included in the study (Table 1). Par-
affin-embedded tumor tissues were obtained from postmeno-
pausal women (aged 60.90 ± 8.96) with endometrial
carcinoma treated in Polish Mothers Memorial Hospital,
Research Institute (PMMH,RI, Lodz, Poland) between 2004
and 2009 years. All tumors were staged according to the criteria
of the International Federation of Gynaecology and Obstetrics
(FIGO). DNA from normal endometrial tissue obtained from
non-cancer patients (n = 50, aged 53.06 ± 4.75) served as
control. Normal endometrial specimens were obtained from
patients who had undergone hysterectomy for intramural leio-
myomas. The Local Ethic Committee approved the study, and
each patient gave a written consent.
DNA isolation
DNA for analysis was obtained from an archival patho-
logical paraffin-embedded tumor and healthy endometrial
samples, which were deparaffinized in xylene and rehy-
drated in ethanol and distilled water. For tissue deparaff-
inization, 1,200 ll xylene was added to tissue section and
agitated for 5 min, then centrifuged at 12,000 rpm for
10 min. The supernatant was removed and fresh xylene
was added, and this step was repeated five times followed
by washing with 100 % ethanol for 10 min and centri-
fuging at 12,000 rpm for 10 min. Then, the tissue pellet
was air-dried. 180 ll of DNA extraction buffer solution
ATL (Qiagen GmbH, Hilden, Germany) was added to the
deparaffinized tissue in a 1.5-ml microcentrifuge tube fol-
lowed by the DNA extraction step. Genomic DNA was
prepared from material by using the commercial QIAmp
DNA Kit (Qiagen GmbH, Hilden, Germany) according to
the manufacturer’s instruction.
Determination of MDM2 genotype
Genotypic analysis of the MDM2 SNP309 (rs2279744)
polymorphism was determined by the PCR-based restriction
fragment length polymorphism (PCR–RFLP) method.
Genome region that includes studied polymorphism was
amplified by PCR using primers 50- CGCGGGAGTTCAGG
GTAAAG-30 and 50-AGCTGGAGACAAGTCAGGACTT
AAC-30 [6, 7]. The PCR (total volume 25 ll) was performed
with a mixture containing about 100 ng of DNA, 12.5 pmol
of each primer, 0.2 mmol/l of dNTPs, 2 mmol/l of MgCl2
and 1 U of Taq DNA polymerase (TaKaRa, Japan). PCR
conditions were as follows: initial denaturation step at 95 C
for 5 min, 35 cycles at 94 C for 30 s and 30 s at the 62 C
annealing temperature, and at 72 C for 30 s. The final
extension step was performed at 72 C for 5 min. The PCR
was carried out in a PTC-100TM (MJ Research, INC, Wal-
tham, MA, USA) thermal cycler. Following PCR, 20-ml
aliquots were removed and subjected to restriction digestion
with MspA1I (BioLabs, New England, Frankfurt am Main,
Germany). The 237-bp amplified product was digested
overnight with 1 U of MspA1I at 37 C. The digested
Table 1 Characteristics of the study population (n = 152)
Characteristics Number of cases (%)
BMI (body mass index) (kg/m2)
\18 0
18–25 21 (14 %)
26–29 60 (39 %)
[30 71 (47 %)
Number of birth
0 48 (32 %)
1 104 (68 %)
[1 0
First menarche
Before 11 years 6 (4 %)
12–13 years 65 (43 %)
14–15 years 71 (47 %)
After 16 years 10 (6 %)
FIGO grade
G1 83 (54 %)
G2 34 (22 %)
G3 35 (23 %)
FIGO stage
I 94 (62 %)
II 36 (24 %)
III 22 (14 %)
Use of hormone replacement therapy—HRT
Yes 96 (63 %)
No 56 (37 %)
Endometrial ultrasound transvaginal—TVU
[5 mm 115 (75 %)
Diabetes mellitus 28 (18 %)
Hypertension 80 (53 %)
Uterine bleeding 100 (65 %)
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products were resolved on a 2 % agarose gel and stained with
0.5 lg/ml ethidium bromide. The wild-type allele T was
identified by the presence of 237-bp band, while the mutant
allele G was represented by 189- and 48-bp bands.
Determination of p53 genotype
The detection of p53 codon 72 (rs1042522) polymorphism
was carried out using PCR–RFLP technique [8, 9]. A 309-bp
fragment from exon 4 of p53 containing codon 72 BstU1
polymorphism site was amplified using the following exon 4
primers: forward primer 50TTC ACC CAT CTA CAG TCC
30 and reverse primer 50CTC AGG GCA ACT GAC CGT 30.
The PCR was carried out in a PTC-100TM (MJ Research,
INC, Waltham, MA, USA) thermal cycler. The 25 ll PCR
mixture contained about 100 ng of DNA, 12.5 pmol of each
primer, 2 ll dNTP (10 mM), 2 mmol/l of MgCl2 and 1 U of
Taq DNA polymerase (TaKaRa, Japan). The PCR cycle
conditions were 94 C for 4 min, initial denaturation and
94 C for 30 s, 62 C for 30 s then 72 C for 30 s, repeated
for 35 cycles. The 309-bp amplified product was digested
overnight with 1 U of BstU1 (BioLabs, New England,
Frankfurt am Main, Germany) at 60 C. After digestion, the
fragments were electrophoresed on 2 % agarose gel and
visualized by UV light after ethidium bromide staining. The
Pro allele was 309 bp, while the Arg allele was restricted into
two fragments of 175 and 134 bp.
Statistical analysis
For each polymorphism, deviation of the genotype fre-
quencies in the controls from those expected under Hardy–
Weinberg equilibrium was assessed using the standard chi-
squared test. Genotype frequencies in cases and controls
were compared by chi-squared tests. The genotypic-spe-
cific risks were estimated as odds ratios (ORs) with asso-
ciated 95 % intervals (CIs) by unconditional logistic
regression. P values \0.05 were considered to be signifi-
cant. Analyses were performed using STATISTICA 10
package (Statsoft, Tulsa, OK, USA).
Results
All the recruited both endometrial cancer (n = 152) and
control samples (n = 50) were successfully analyzed for
the TP53 and MDM2 genotype. From the PCR analysis, all
patients were classified into three genotypes of the MDM2
and TP53 gene: G/G, G/T and T/T and Pro/Pro, Pro/Arg
and Arg/Arg, respectively.
It can be seen from Table 2 that there are significant
differences in the frequency of TP53 and MDM2 genotypes
(p \ 0.05). An association was observed between endo-
metrial carcinoma occurrence and the presence of G/G and
Arg/Arg genotypes (Tables 3, 4, 5). Variant Pro allele of
TP53 decreased cancer risk (Table 3).
We also analyzed combined genotype of all polymor-
phism pairs. The combined T/T-Pro/Arg genotype
decreased the risk of endometrial cancer occurrence
(Table 5). Moreover, the combined G/G-Arg/Arg genotype
increased the risk of EC (Table 6).
The observed genotype frequency of TP53 codon 72
(p [ 0.05) as well as MDM2 SNP309 in the controls group
was in agreement with Hardy–Weinberg equilibrium
(HWE) (p [ 0.05). In case of both investigated genes, the
distribution of the genotypes in the patients differed sig-
nificantly from the one expected from the Hardy–Weinberg
equilibrium (p \ 0.05).
Table 2 Distribution of TP53-Pro/Arg and MDM2-G/T genotypes in
patients with EC
G/G G/G (%) T/G T/G (%) T/T T/T (%)
Pro/Pro 37.00 0.37 10.00 0.33 16.00 0.66
Arg/Arg 31.00 0.31 12.00 0.4 7.00 0.29
Pro 104.00 0.53 28.00 0.46 33.00 0.68
Arg 92.00 0.46 32.00 0.53 15.00 0.31
chi2/p 14.56 0.0002 6.47 0.02 19.57 0.00009
Pro/Arg 30.00 0.30 1.00 0.04
Arg/Pro 8.00 0.26
Bold values are statistically significant (p \ 0.05)
Table 3 Distribution of genotypes and odds ratios (OR) of the TP53-Pro/Arg polymorphism in patients with MDM2-G/G homozygous variant
and controls
G/G Controls OR X2.5.. X97.5 Z value Pr…z..
Pro/Pro 37.00 22.00 0.77 0.39 1.55 -0.73 0.46
Pro/Arg 30.00 21.00 0.61 0.30 1.24 -1.37 0.16
Arg/Arg 31.00 7.00 2.84 1.20 7.54 2.26 0.02
Pro 104.00 65.00 0.35 0.13 0.83 -2.26 0.02
Arg 92.00 35.00 1.30 0.65 2.59 0.73 0.46
Bold values are statistically significant (p \ 0.05)
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It is caused by the very low abundance of the TP53 Pro/
Pro genotype and MDM2 T/T genotype in the examined
Polish population.
Because we were interested in the association between
the distribution of genotypes and frequencies of alleles of
investigated genetic variability on the tumor grade evalu-
ated according to FIGO criteria, these data were also
analyzed. Histological grading was evaluated in all the
cases (n = 152): grade 1 (G1)—83 cases, grade 2 (G2)—
34 cases and grade 3 (G3)—35 cases (see Table 7). Some
correlation was observed between the TP53 Pro/Arg and
MDM2 G/T genotype and EC invasiveness. A strong
increase was observed, regarding G/G homozygotes fre-
quency and Arg/Arg homozygotes in G2 patients. That
increase was statistically significant (p \ 0.05). Moreover,
EC patients in G1 and G2 had an overrepresentation of G
alleles.
Clinical FIGO staging was also related to MDM2 G/T
and the TP53 Pro/Arg polymorphisms (Table 8). Staging
was evaluated in all the cases (n = 152). An increase was
observed, regarding G/G and Arg/Arg homozygotes fre-
quency in staging I (SI) patients, according FIGO
classification. That increase was statistically significant
(p \ 0.05). Moreover, in case of TP53, an increase was
observed, regarding Arg/Arg homozygotes frequency in
FIGO staging II (SII). That increase was also statistically
significant (p \ 0.05).
Our data did not demonstrate any statistically significant
correlation between MDM2 and TP53 polymorphisms and
the risk factors for endometrial cancer, such as body mass
index, hormone replacement therapy, uterine bleeding,
endometrial transvaginal ultrasound, diabetes and hyper-
tension and women with endometrial cancer (data not
shown).
Discussion
The authors coping with genetic background of EC found
that both MDM2 and TP53 polymorphisms are associated
with the risk of this female neoplasm when evaluated
separately.
In case of MDM2–EC relationship, an American publi-
cation by Walsh et al. [10] found that the presence of
Table 5 Distribution of genotypes and odds ratios (OR) of the TP53-Pro/Arg polymorphism in patients with MDM2-T/T homozygous variant
and controls
T/T Controls OR X2.5.. X97.5 Z value Pr…z..
Pro/Pro 16.00 22.00 2.55 0.94 7.31 1.80 0.07
Pro/Arg 1.00 21.00 0.06 0.00 0.32 -2.65 0.008
Arg/Arg 7.00 7.00 2.53 0.76 8.49 1.53 0.12
Pro 33.00 65.00 0.40 0.12 1.31 -1.53 0.12
Arg 15.00 35.00 0.39 0.14 1.06 -1.80 0.07
Bold value is statistically significant (p \ 0.05)
Table 6 Distribution of MDM2-G/G and TP53-Arg/Arg genotypes and odds ratios (OR) in patients with EC and controls
Patients Controls OR X2.5.. X97.5 Z value Pr…z..
G/G 98 14 4.79 2.39 10.06 4.30 0.000016
Arg/Arg 50 7 3.16 1.35 8.39 2.50 0.01
Bold values are statistically significant (p \ 0.05)
Table 4 Distribution of genotypes and odds ratios (OR) of the TP53-Pro/Arg polymorphism in patients with MDM2-T/G heterozygous variant
and controls
T/G Controls OR X2.5.. X97.5 Z value Pr…z..
Arg/Arg 12.00 7.00 4.10 1.42 12.66 2.55 0.01
Pro/Pro 10.00 22.00 0.64 0.24 1.61 -0.94 0.34
Arg 32.00 35.00 1.57 0.62 4.14 0.94 0.34
Pro 28.00 65.00 0.24 0.08 0.70 -2.55 0.01
Bold values are statistically significant (p \ 0.05)
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homozygous MDM2 SNP309 G/G genotype is quite fre-
quent—25 % in EC cases (11 % in controls), increasing the
EC risk up to 2.76, having no association with EC grading
and staging as well as patient’s age at diagnosis. Also,
another American publication by Terry et al. [11], nested
within two large case–control studies—WHS (Women’s
Health Study) and NHS (Nurses’ Health Study) with a total
number of 592 EC cases and 1.543 controls, reported
increased EC risk (OR = 1.87) in women with G/G geno-
type of MDM2 SNP309 polymorphism. In a Japanese report
by Ueda et al. [12], both G/G genotype and G allele
increased the risk of EC development, with OR = 1.91 and
1.20, respectively. In this study, homozygous G/G genotype
was positively associated with postmenopausal status and
EC type I alike, suggesting that this kind of MDM2 SNP309
polymorphism could be a risk factor for EC type I in Jap-
anese female population [12]. These results are in accor-
dance with our previous reports, indicating that both G/G
genotype and G allele are highly associated with increased
EC risk in Polish women, OR—3.50 and 2.67, respectively.
No relationship of this MDM2 SNP309 polymorphism with
EC grading was observed by us in this study [4].
But if it comes to TP53-EC association, high TP53
expression was observed by Kudela et al. [13] in poorly
differentiated (G3) EC tumors. According to these Czech
researchers, TP53 may serve as one of the genetic markers
responsible for differentiation of patients with bad EC
prognosis [13]. Having found two meta-analyzes on TP53
polymorphism-EC linkage, the authors of the first one did
not observe any correlation between EC risk and TP53
codon 72 polymorphism (although further studies in larger
number of patients are recommended) [14], while the
second report varies, combining Pro allele and Pro carriers
(Pro/Pro, Arg/Pro) with increased EC risk (OR = 1.25 and
1.34, respectively) [15].
From the current point of view, it seems to be more
important to analyze the studies focusing on the combined
effect of TP53 and MDM2 polymorphisms in EC. Ashton
et al. [16] reported that the combination of MDM2
SNP309 and three TP53 codon 72 polymorphisms is
associated with a higher grade of EC (OR = 4,15). The
Australian researchers found also the association between
family history of breast cancer and TP53 polymorphisms,
suggesting a low-risk familial cancer grouping in this case
Table 8 Dependency of MDM2-G/G and TP53-Arg/Arg genotypes on the tumor staging in patients with EC
Controls OR X2.5.. X97.5 Z value Pr…z..
Staging I
G/G 67 14 6.95 3.24 15.67 4.85 0.0000012
Arg/Arg 27 7 2.84 1.09 8.22 2.05 0.04
Staging II
G/G 9 14 1.71 0.56 5.18 0.96 0.33
Arg/Arg 9 7 4.18 1.30 14.06 2.39 0.017
Staging III
G/G 2 14 0.38 0.05 5.18 -1.16 0.25
Arg/Arg 5 7 3.18 0.79 12.67 1.66 0.10
Bold values are statistically significant (p \ 0.05)
Table 7 Dependency of MDM2-G/G and TP53-Arg/Arg genotypes on the tumor grading in patients with EC
Controls OR X2.5.. X97.5 Z value Pr…z..
Grading G1
G/G 44 14 5.19 2.35 12.00 3.98 0.000069
Arg/Arg 17 7 2.19 0.80 6.56 1.48 0.14
Grading G2
G/G 23 14 2.82 1.17 7.11 2.26 0.02
Arg/Arg 19 7 4.68 1.74 13.84 2.95 0.0031
Grading G3
G/G 14 14 4.99 1.68 16.14 2.81 0.0049
Arg/Arg 7 7 2.89 0.78 10.97 1.59 0.11
Bold values are statistically significant (p \ 0.05)
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(OR = 2.78) [16]. Nunobiki et al. calculated that homo-
zygous TP53 codon 72 Arg/Arg genotype together with
homozygous MDM2 SNP309 G/G polymorphism is
responsible for significantly enhanced EC risk
(OR = 3.28). The Japanese scientists concluded that these
two polymorphisms may cooperatively increase the risk
of EC among Japanese women [17]. Similar results were
presented by Yoneda et al. [18] founding that the com-
bination of TP53 codon 72 Arg/Arg and MDM2 SNP309
G/G?T/G significantly enhances the risk of EC
(OR = 2.53).
Our results not only confirmed the fact that MDM2
SNP309 G/G plus TP53 codon 72 Arg/Arg genotype
increases EC risk, but also showed that MDM2 SNP309
T/T plus TP53 codon 72 Pro/Arg genotype could decrease
its risk. Additionally, some important connections with
grading (GI–GIII) and staging (SI–SII) of EC were
presented.
Conclusions
The co-occurrence of selected gene polymorphisms of
MDM2 SNP309 and TP53 codon 72 may influence the risk
of EC, having also a relationship with grading and staging
of this cancer.
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